These interviews highlight the depth and range of experience within Advanced Oncotherapy’s Board and Executive management teams. They also proffer insight into the goals, challenges and opportunities ahead in the commercialisation of LIGHT.

Following the new appointment at Advanced Oncotherapy Plc (LON:AVO) as Senior Independent Non-Executive Director, Mr Hans von Celsing talks about his past experience, the present and his thoughts on the future of the company.

Q: Hans, could you tell us about your experience in radiotherapy and how that relates to your role as an adviser to Advanced Oncotherapy?

A: I have spent most of my career in radiotherapy and have been involved in this market since the mid-80s. I joined Elekta in the early stages of its development and helped grow the business to a global radiotherapy company with a market capitalisation of 30 billion Swedish kroner. I was also involved in the development and promotion of the Gamma Knife, with the aim of creating radiotherapy systems for neurological indications with more accurate tumour targeting and in advanced imaging/3-D positioning systems.

Q: And in addition to Elekta?

A: I was also involved with Mevion at an early stage and helped it in its international development effort. Mevion technology was an important step in making proton therapy systems clinically affordable on a broader scale.

Q: So you have seen the full spectrum of radiotherapy applications and systems: from small start-ups to big corporations and from state-of-the-art radiotherapy systems with advanced treatment room facilities to one-room proton therapy systems?

A: That’s correct.

Q: So you must have seen a lot of changes and evolution in the field of radiotherapy?

A: Absolutely! When I started out in the 80’s, radiotherapy was not a favourable treatment choice. Patients treated by radiotherapy were generally very sick and were some of the worst cancer cases. Radiotherapy had many side effects and outcomes were often not that favourable.

Q: Why was this the case?

A: One of the biggest issues was accuracy of beam delivery and tumour targeting. The imaging systems and computing power used to deliver radiation beams to the tumour site were considerably less accurate by today’s standards. Excessive doses could be delivered to healthy surrounding tissue, with consequential and unwanted side effects.

I am pleased to say there have been many advances in beam targeting and improvements in this area will lead to more accurate dose delivery and improved patient outcomes. The LIGHT system has the potential to provide a further leap forward in the accuracy of tumour targeting.

Q: So Elekta, then Mevion, and now you’re helping Advanced Oncotherapy. Why AVO?

A: AVO and its LIGHT system is amazing technology and offer a great opportunity for the advancement of proton and particle therapy technology. AVO is developing a Linac–based (linear accelerator) proton therapy system; all other competing proton therapy systems use cyclotrons, synchrocyclotron or synchrotron accelerators. This group originated from physics laboratory experiments. A Linac system is designed specifically for medical use and lends itself extremely well to cancer therapy. I also see much of the excitement at AVO that I did when Elekta and Mevion were at similar stages of their development.

Q: So what are some of the key features of LIGHT?

A: One is the ability to electronically control the energy delivered to the tumour site. This energy can be changed rapidly both in terms of energy amount and energy positioning without the need for physical absorbers or other methods. The required dose can be delivered to the exact site many, many times per second.

LIGHT is also an integrated system. An all-in-one or integrated solution, which provides a system for beam production, treatment planning and accurate beam delivery reduces the risk of errors arising in interoperability between different systems. The treatment planning software and solution that is being developed is, I believe, state-of-the-art. It is simple and its one-touch, one-screen panel will enable radiotherapists and radiation oncologists to devise the best treatment solutions for their patients. The ability to serve multiple treatment rooms is another key feature; the LIGHT system can power up to five treatment rooms, thereby reducing the incremental cost for each room.

Q: Ok. So what’s the significance of this in relation to the potential take-up of LIGHT?

A: The economics of any treatment are critical in many healthcare decisions. It is also not just the incremental cost of each room which is relevant. By virtue of being linear, compact and modular, LIGHT lends itself to easier installation and, hence, lower building/installation costs.

Q: What do you think the future holds in store for Advanced Oncotherapy plc? What should they do next?

A: Essentially what they are already doing. Sticking to their plan of building their first machine, with first installation due at Harley Street, London, integrate imaging for adaptive therapy planning and to continue to generate interest globally for the LIGHT Proton Therapy system.

Michel Baelen, head of Regulatory Affairs at Advanced Oncotherapy plc (LON:AVO), talks about the attraction of joining AVO, his past roles and how this experience benefits the company, work done to date and Michel’s plans for regulatory and quality control going forward.

Q: Michel, what attracted you to join AVO?

A:The development of the proton beam therapy system LIGHT, with its innovative and clinically superior approach to the treatment of cancer.

Q: So how does the position fit to what you have done previously?

A: I have a background in electronic engineering and was responsible for IBA’s regulatory and quality assurance affairs for 19 years.

Q: Can you tell us what IBA is?

A: IBA is the current market leader in proton beam therapy. As well as working at IBA, I was previously head of the European Commissions’ industry association for medical devices and worked in a regulatory/quality capacity assurance at the IAEA (International Atomic Energy Agency).

Q: So how does your experience benefit AVO and its investors?

A: Having worked on both sides of the regulatory fence I know exactly what AVO must do to meet all regulatory and quality control requirements.

Q: In that regard, what have you been doing so far?

A:We’ve been in dialogue with the major regulatory bodies and have been working through what we, AVO, must do to ensure we meet their requirements in as efficient and timely manner as possible.

Q: Can we expect any newsflow to that effect?

A:Absolutely, although timing is difficult to predict; we have been very busy in this regard and hope to make announcements to this end.

Q: On the LIGHT system itself, can you tell us some of the key features that will differentiate it from its competitors?

A: From a safety perspective, the ability to monitor the exact nature of the proton beam and completely control its transmission i.e. if the beam needs to be shut off, we will be able to ensure the patient receives no dose at all. Another is to vary the energy of the beam and, accordingly, the dose the target tumour receives at very high frequencies, for more accurate tumour targeting.

Q: For any new technology with the potential to disrupt a market, there must be risks associated with the realisation of that technology?

A:The development of LIGHT will be a process and there are challenges ahead. For example, the accelerating modules will contain a vacuum at much lower pressure than is present in existing radiotherapy systems. In addition, the ability to vary the energy of the proton beam with every pulse requires highly sophisticated and robust software control and management.

Q: Are there any other key safety USPs?

A:Yes, the LIGHT system will not suffer from comparable proton losses and, as a result, will not irradiate and physically/chemically alter, otherwise known as activate, the shielding and surrounding materials that any radiotherapy system is housed in. For example, the decommissioning costs of non-Linac proton accelerators can be up to three times as high as the initial cost. So that can be a major headache for hospitals and clinics; LIGHT is the only proton therapy system using a linear particle accelerator.

Q: And given the potential hurdles inherent in LIGHT’s development, what is AVO doing to manage and overcome those risks?

A: Two key approaches adopted by Advanced Oncotherapy have been to hire industry experts, in all relevant fields, and to partner market leading companies, such as Thales. For example, Thales, which will mass produce LIGHT for AVO, has already demonstrated its ability to create a vacuum at the required level that I previously referred to. We have also hired an expert in safety-critical software from Airbus, a market leader in another industry where it is absolutely essential that software, and the systems that that software controls, perform precisely as required.

Q: Is there anything else you’d like to highlight?

A: Just that we, AVO, are doing everything we can to ensure we clear all regulatory and quality control hurdles in all major markets and with all relevant bodies, globally. Michel, thank you for your time.

Advanced Oncotherapy PLC (LON:AVO) subsidiary ADAM S.A. Executive Chairman professor Steve Myers discusses the LIGHT system, its likely impact, its design, the progress being made and its future.

Q: Professor Myers, you became Executive Chairman of ADAM S.A. (ADAM), the CERN spin-off and Advanced Oncotherapy’s (AVO’s) subsidiary, in late 2015, and joined

AVO’s Board earlier this year. Your primary responsibility is overseeing the development of AVO’s proprietary and novel proton beam therapy (PBT) technology, LIGHT?

A: Yes, that’s right. The single most important aspect of LIGHT is that it is based on a fundamentally different design to all other PBT systems. All existing technologies are based on cyclotrons or synchrotrons; LIGHT is the only linear proton accelerator designed for medical application in the treatment of cancer.

Q: Does that matter?

A: It matters a great deal. These differences, in terms of technology and costs, have major implications for LIGHT’s potential disruption of the global radiotherapy market. Its technology provides a paradigm shift in clinical effectiveness: the speed at which the energy and direction of the beam can be modulated, the production of secondary radiation, shielding requirements, beam size, size of magnets along the beam transfer line and, hence, the size of the patient gantry, these are all radically better with a linear accelerator.

Costs, in regards to upfront capital expenditure, ongoing maintenance and decommissioning, have also proven prohibitively high for hospitals and clinics when considering existing technologies. LIGHT will be available at a fraction of the cost of comparable competing systems.

Q: So why aren’t there more linear proton accelerators in hospitals?

A: From a design perspective, it’s because the engineering behind LIGHT is sufficiently challenging that it has taken the expertise within ADAM, and the experience of continually designing, creating and operating next-generation particle accelerators, to build one.

Q: How has that expertise translated into LIGHT’s design; can you highlight some examples?

A: There are a lot, but to pick just one of LIGHT’s components as an example, in February ‘17 we reached a major technical milestone by hitting the desired output energy from the RFQ (Radio Frequency Quadrupole). The RFQ has a number of unique properties: operating at 750 MHz, so it is far smaller than comparable systems, and the energy of the proton beam can be altered 200 times every second, for more accurate tumour targeting and adaptive treatment.

Q: So where are we with LIGHT?

A: We outlined the milestones we’re working towards at the investor evenings in March 2017 and hitting those is very much our focus. We updated the market with the progress we have made on the patient positioning system, ionisation chamber and RFQ on June 12th 2017; we’ll be providing further updates on milestones in due course.

Q: So a major technical event will be generating a proton beam of sufficient energy to treat superficial tumours later in 2018?

A: That’s right.

Q: And then, once the first machine has been produced?

A: There is a huge, unmet medical need for new PBT systems and AVO has been putting the foundations in place to cope with this demand. At the same time, we will keep innovating and continue leveraging LIGHT’s unique capabilities. A potential future addition to LIGHT could be the ability to generate a beam of heavier ions, with higher relative biological effectiveness than even protons. Other enhancements could include enhanced accelerating power and, therefore, a shorter LIGHT system or more efficient radiofrequency generators to reduce already low operating costs. LIGHT’s modular nature lends itself perfectly to the possibility of upgrades and to further improved clinical benefits and/or lower costs.

But, I should stress that the Advanced Oncotherapy PLC LIGHT is already sufficiently different to existing technology to be hugely disruptive in the current market. Getting LIGHT into mass production is what we’ll be concentrating on.

Advanced Oncotherapy PLC (LON:AVO) Chief Executive Officer, Nicolas Serandour, highlights the opportunities ahead, the challenges AVO has faced, what’s been done to overcome those obstacles and what the future might hold for the Company and its shareholders.

Q: Nicolas, you became CEO in October last year; a lot has happened since then, including technical developments, an updated timetable at Harley Street and new financing. You’ve clearly been busy, yes?

A: Yes, that’s right, although the same can be said of the whole team at Advanced Oncotherapy. We reached a number of major milestones in the development of LIGHT, gave a more detailed, and revised timetable for our flagship Harley Street centre and have made considerable progress in the redevelopment of the Harley Street site.

AVO has had challenges as well and some are not uncommon for companies of similar size and maturity. The priority for me, the Board and executive team is managing the transition from an R&D-focused company into one with a clear commercial goal. Some changes have been necessary, as has continuing to capitalise on the world-leading scientific expertise within ADAM, the CERN spin-off and AVO subsidiary.

Q: What have you done to overcome the challenges?

A: The first step was to focus on our priorities. It’s important for smaller companies to have a clear understanding of what really matters and to stick to that, so we’ve focused on what will advance the project as safely, efficiently and cost-effectively as possible.

As a consequence, two key areas in particular have been strengthened: personnel and regulatory engagement. For example, we’ve reorganised teams to work on a functional rather than simply a reporting basis, made a number of key hires and concentrated on accountability and KPIs.

Those hires have included experts in medical device regulation, with a view to ensuring regulatory compliance. As a result, we have had several meetings with regulatory bodies in Europe, the US and in China, which have given us confidence we are pursuing a valid path to regulatory approval.

Q: So where does that leave AVO; how would you describe the opportunity for the Company and its ability to capitalise on it?

A:The opportunity is, unquestionably, enormous. We are uniquely placed to upset the status quo in the global radiotherapy market, by offering a proton therapy system that is radically different to existing machines. In turn, this has major implications for potential costs/ease of installation for hospitals and clinics and for clinical benefits for patients.

Completing the first LIGHT system according to the schedule we outlined in our investor event in March this year will help us to maximise our commercial opportunities. We’re making great progress in this regard and have already reached a number of key milestones.

Terminating discussions in China was obviously disappointing, but was the right thing to do. It is a key market and one we’ll undoubtedly return to given the potential demand there and we’re making great progress in other countries. The opportunity is global.

Opportunities don’t automatically translate into commercial realities, however; the right decisions must be taken to realise potential. That’s why we have entered into partnerships with market leading companies. They bring the commercial know-how that will help us to rapidly reduce operating costs and accelerate the production ramp-up. In addition, the right people are necessary to make AVO the success it will be and I’m fortunate to work with a very talented group. Together, we execute the strategy our Board has set out.

Q: And what next for AVO?

A:We need to continue on the path I set when I became CEO. That means hitting the technical milestones and construction timetable at Harley Street, the site of our flagship project, strengthening our financing platform and pursuing commercial opportunities globally. We will keep the market updated with our progress and I’m convinced that by delivering on each of these steps we will deliver, to the benefit of all shareholders and to cancer sufferers here in the UK and around the world.

To make the most of this opportunity, we need to strive for excellence: “Winning requires a crystal clear vision, relentless passion and complete dedication with no excuses.”